Please type a plus sign (+) inside this box ->	1	_

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary) Sheet of

Complete if Known				
Application Number	10/808,681			
Filing Date	March 25, 2004			
First Named Inventor	Carl G. FIGDOR et al.			
Group Art Unit	1643			
Examiner Name	Stephen L. Rawlings			
Attorney Docket Number	703329			

			J.S. PATENT DOCUMENTS		
Doc. No.	U.S. Patent Document				T
	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of	i ining Dute
A1	5,639,860		Tanaka et al.		Appropriate
A 2	5,643,873				
A 3	5,648,458				
A 4	5,728,802				
A 5	6,194,195	B1			
A 6	2003/0096787	A1	Perricaudet et al.		
				GOIZZIZOOO	
	A1 A2 A3 A4 A5	A 1 5,639,860 A 2 5,643,873 A 3 5,648,458 A 4 5,728,802 A 5 6,194,195	A 1 5,639,860 A 2 5,643,873 A 3 5,648,458 A 4 5,728,802 A 5 6,194,195 B1	A1 5,639,860 Tanaka et al. A2 5,643,873 Barrett et al. A3 5,648,458 Cwirla et al. A4 5,728,802 Barrett et al. A5 6,194,195 B1 Tanaka et al.	A1 5,639,860 Tanaka et al. 06/17/1997 A2 5,643,873 Barrett et al. 07/01/1997 A3 5,648,458 Cwirla et al. 07/15/1997 A4 5,728,802 Barrett et al. 03/17/1998 A5 6,194,195 B1 Tanaka et al. 02/27/2001

Examiner		Foreign Patent Document					Translation	
Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No*+
	A 7	CA	2 053 187		National Research Council of CA	04/11/1993	-	
	A 8	FR	2 707 664		Centre Nat. Rech. Scient. (FR); Roussy Inst. Gustave	01/20/1995		+
				 				

	·	OTHER - NON PATENT LITERATURE DOCUMENTS		
IIIIIIais	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number (s)		lation
		publisher, city and/or country where published	Yes	No*+
	A 9	TRAVERSARI, C., et al., "A Nonapeptide Encoded by Human Gene MAGE-1 Is Recognized on HLA-A1 by Cytolytic T Lymphocytes Directed against Tumor Antigen MZ2-E", J. Exp. Med., Volume 176, 1453-1457 (November 1992)		
	A10	Notice of Opposition to European Patent No. EP0668350; Date of mention of the grant in the European Patent Bulletin July 28, 2004		
	A11	Opposition of EP0668350 in the name of Crucell Holland B.V. for Opponent Oxxon Therapenitcs Limited		
	A12	MPSRCH Search Report Seq ID No. 22, p. 1-3 (2001)		
	A 1 3	MPSRCH Search Report, for Seq ID No. 21, p. 1-2 (2001)		
	A14	European Search Report, EP 94 20 0337, dated 27 July 1994		

Examiner Signature	Date Considered
<u></u>	
* ^	

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

⁺ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).